Verastem

Verastem, Inc. is a biopharmaceutical company, which engages in the development and commercialization of drugs for the treatment of cancer. The company was founded by Richard H. Aldrich, Michelle Dipp, Piyush Gupta, Satish Jindal, Eric S. Lander, Robert F. Weinberg, and Christoph H. Westphal on August 4, 2010 and is headquartered in Needham, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today reported financial results for the three months ended March 31, 2022 and highlighted recent progress. “In the first quarter of this year, we made significant progress building on our breakthrough therapy designation in recurrent low-grade serous ovarian cancer and advancing our development programs and scientific platform to establish VS-676

Verastem Oncology Reports First Quarter 2022 Financial Results and Highlights Recent Company Progress

Verastem recently reported their Q4 and full-year 2021 earnings that revealed substantial headway in their pipeline and on the balance sheet. Verastem secured up to $150M in non-dilutive funding from Oxford Finance. Now, the company expects their cash runway to last through 2025.

Verastem: Time To Take My Position Out Of Mothball

Agriforce Growing Systems Ltd

CEL-SCI

Are these high-volume penny stocks on your buy list right now? The post 3 Penny Stocks to Watch With Above Average Volume Today  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

3 Penny Stocks to Watch With Above Average Volume Today

Gran Tierra Energy

Sonim Technologies Inc

Here are three penny stocks under $2 to watch right now The post Top Penny Stocks Under $2 to Watch As Inflation Rises appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Top Penny Stocks Under $2 to Watch As Inflation Rises

Verastem Oncology Inc (NASDAQ: VSTM) entered into a credit facility with Oxford Finance LLC for up to $150 million to primarily support the continued development, commercial preparation, and potential launches of VS-6766 and defactinib. Verastem drew an initial $25 million.

Verastem Announces $150M Debt Financing To Support VS-6766, Defactinib Development

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today reported financial results for the three months and full year ended December 31, 2021, and highlighted recent progress. “We anticipate a catalyst-driven year and are well-positioned to maximize the potential of VS-6766 as a backbone therapy across RAS pathway-driven solid tumors in order to bring new solutions to patients in areas of high un

Verastem Oncology Reports Fourth Quarter and Full Year 2021 Financial Results and Highlights Recent Company Progress

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced it has entered into a credit facility with Oxford Finance LLC for up to $150 million that is designed to primarily support the continued development, commercial preparation and potential launches of VS-6766 and defactinib. “The term loan facility with Oxford is an ideal non-dilutive opportunity for Verastem. Combined with our stron

Verastem Oncology Provides Financial Update to Support Development of VS-6766 and Defactinib in RAS Pathway-Driven Tumors

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced that Channing Der, PhD, has been appointed to its Scientific Advisory Board. Dr. Der, a preeminent researcher in the science of RAS pathway signaling and rational drug combinations, will provide expert guidance as Verastem advances its work in RAS pathway-driven cancers, including lead compound, RAF/MEK clamp VS-6766. Dr. Der is

Verastem Oncology Names Preeminent Oncology Researcher Channing Der, PhD, to its Scientific Advisory Board

Truist has initiated coverage on Verastem Oncology Inc (NASDAQ: VSTM) with a Buy rating and $6.00 price target, equivalent to approximately 350% upside. Analyst Srikripa Devarakonda notes that trading at about 2-times cash, the stock is "undervalued" given its programs in.

Truist Sees 350% Upside On This Cancer-Focused Biopharma Stock - Read Why

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today outlined key strategic priorities and upcoming catalysts to support its lead compound VS-6766 in 2022. VS-6766 is a RAF/MEK clamp that induces inactive complexes of MEK with ARAF, BRAF and CRAF, potentially creating a more complete and durable anti-tumor response through maximal RAS pathway inhibition. VS-6766 is currently in late-stage d

Verastem Oncology Outlines Key 2022 Strategic Priorities and Upcoming Catalysts for Advancing VS-6766 as a Backbone of Therapy for RAS Pathway-Driven Cancers

Mirati Therapeutics

Mirati Therapeutics (MRTX) partners Verastem Oncology (VSTM) to evaluate adagrasib in combination with VS-6766 in KRASG12C-mutant non-small cell lung cancer.

Mirati (MRTX), Verastem to Study Cancer Drugs for NSCLC

SAN DIEGO and BOSTON, Nov. 22, 2021 /PRNewswire/ -- Mirati Therapeutics, Inc. (Nasdaq:MRTX), a clinical-stage targeted oncology company and Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced a non-exclusive clinical collaboration agreement to evaluate the combination of Mirati's investigational KRASG12C inhibitor adagrasib with Verastem Oncology's investigational RAF/MEK inhibitor VS-6766 in KRASG12C-mutant non-small cell lung cancer (NSCLC). The primary objective of this multi-center, single-arm, open-label Phase 1/2 trial is to determine the maximum tolerated dose and recommended Phase 2 dose for the combination of adagrasib and VS-6766 in patients with KRASG12C-mutant NSCLC.

Mirati Therapeutics and Verastem Oncology Partner to Evaluate Adagrasib in Combination with VS-6766 in KRASG12C-Mutant Non-Small Cell Lung Cancer

Digital Turbine

Celsius Holdings

Dow Inc

Enphase Energy

Intrepid Potash

Centrus Energy

Li Auto Inc.

Oncternal Therapeutics Inc

Ammo

Two new Breakout Stocks for Week 46 with better than 10% short-term upside potential. The ETF/ETN forecast section now goes out in a separate article. Following the Daily Momentum Gauges® the portfolio is up +70.5% YTD despite a record high 24 weeks out 45 weeks this year in negative conditions above the 40 MG level.

Week 46 MDA Breakout Stocks - November 2021: Short-Term Picks To Give You An Edge

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced that the Company will present at the Jefferies London Healthcare Conference. The presentation will be made available for on-demand listening beginning Thursday, November 18, 2021 at 8:00 a.m. GMT (3:00 a.m. ET). A webcast of the presentation will be available on investors section of the Company's website at www.verastem.com. An

Verastem Oncology to Present at the Jefferies London Healthcare Conference

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today reported financial results for the three months ended September 30, 2021 and highlighted recent progress. “The third quarter was marked by several significant milestones for Verastem as we continued to advance our development program to establish VS-6766 as a backbone therapy across RAS pathway-driven solid tumors, including our entry into a

Verastem Oncology Reports Third Quarter 2021 Financial Results and Highlights Recent Company Progress

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced the appointment of Michelle Robertson to its Board of Directors, effective November 15, 2021. Ms. Robertson, who is the Chief Financial Officer at Editas Medicine, will chair the audit committee. She will fill a vacancy created by Gina Consylman, who is stepping down from the Board later this year to focus on other professional

Verastem Oncology Appoints Michelle Robertson to Board of Directors

Adaptimmune Therapeutics

Corvus Pharmaceuticals

These three low-priced cancer stocks could be grossly undervalued.

3 Biotech Stocks That Could Make You Filthy Rich

Verastem Oncology has had a relatively quiet year for most of 2021 but a pair of announcements has provided a burst of excitement that could revitalize investor sentiment.

Verastem: Buying Opportunity Following Unjustified Sell-Off

Dermata Therapeutics

9 Meters Biopharma

Zynerba Pharmaceuticals

Analysts say these are penny stocks to buy right now. The post Top Penny Stocks To Buy The Dip According To Analysts In September appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Top Penny Stocks To Buy The Dip According To Analysts In September

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the appointment of Louis J. Denis, M.D., as Chief Medical Officer. Dr. Denis brings more than 25 years of clinical development and oncology expertise to Verastem. “Louis' proven track record in drug development, including targeting the RAS pathway for treatment of cancer, and his background as a medical oncologist will be invaluable

Verastem Oncology Appoints Louis J. Denis, M.D.

A clinical collaboration with biotech titan Amgen briefly lit a fire underneath Verastem's shares today.

Why Verastem Stock Spiked Today

Verastem (VSTM) stock is on the rise Monday morning following an announcement from the company concerning a deal with Amgen (AMGN). The post Penny Biotech Stocks: 8 Things for Verastem Investors to Know as VSTM Stock Shoots Higher appeared first on InvestorPlace.

Penny Biotech Stocks: 8 Things for Verastem Investors to Know as VSTM Stock Shoots Higher

The stock price of Verastem Inc (NASDAQ: VSTM) increased by over 20% pre-market today. This is why it happened.

VSTM Stock: Why It Significantly Increased Today

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced a clinical collaboration agreement with Amgen to evaluate the combination of VS-6766, Verastem Oncology's investigational dual RAF/MEK inhibitor, with Amgen's KRAS G12C inhibitor LUMAKRASTM (sotorasib) in KRAS G12C-mutant non-small cell lung cancer (NSCLC). The Phase 1/2 trial will evaluate the safety, tolerability and efficacy

Verastem Oncology and Amgen Partner to Evaluate VS-6766 in Combination with LUMAKRASTM (Sotorasib) in Patients with KRAS G12C-Mutant Non-Small Cell Lung Cancer

Verastem Oncology Inc (NASDAQ: VSTM) stock is trading higher after updated data from the ongoing Phase 1/2 FRAME study.  The investigator-sponsored study is investigating VS-6766, Verastem's RAF/MEK inhibitor, in combination with defactinib, its FAK inhibitor, in patients with low-grade serous ovarian cancer (LGSOC).

Verastem Shares Are Trading Higher On Encouraging Combo Therapy Data At ESMO Presentation

News for Verastem Stock (VSTM)